Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Executive Summary
Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.